Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Common Equity (2016 - 2025)

Historic Common Equity for Usana Health Sciences (USNA) over the last 16 years, with Q3 2025 value amounting to $528.1 million.

  • Usana Health Sciences' Common Equity fell 94.04% to $528.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $528.1 million, marking a year-over-year decrease of 94.04%. This contributed to the annual value of $532.1 million for FY2024, which is 702.07% up from last year.
  • As of Q3 2025, Usana Health Sciences' Common Equity stood at $528.1 million, which was down 94.04% from $531.1 million recorded in Q2 2025.
  • In the past 5 years, Usana Health Sciences' Common Equity registered a high of $533.1 million during Q3 2024, and its lowest value of $389.9 million during Q2 2022.
  • Moreover, its 5-year median value for Common Equity was $462.1 million (2023), whereas its average is $462.7 million.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 2681.58% in 2021, then crashed by 1053.46% in 2022.
  • Quarter analysis of 5 years shows Usana Health Sciences' Common Equity stood at $399.1 million in 2021, then grew by 8.87% to $434.5 million in 2022, then rose by 14.44% to $497.2 million in 2023, then grew by 7.02% to $532.1 million in 2024, then decreased by 0.76% to $528.1 million in 2025.
  • Its Common Equity stands at $528.1 million for Q3 2025, versus $531.1 million for Q2 2025 and $529.8 million for Q1 2025.